Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option

Robert J Hamilton; Michael A S Jewett; Padraig Warde; Aaron Hansen

doi:10.1016/j.euf.2019.05.003

Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option

Eur Urol Focus. 2019 Sep;5(5):702-703. doi: 10.1016/j.euf.2019.05.003. Epub 2019 May 22.

Authors

Robert J Hamilton¹, Michael A S Jewett², Padraig Warde³, Aaron Hansen⁴

Affiliations

¹ Department of Surgery (Urology), Princess Margaret Cancer Centre, University Health Network and The University of Toronto, Toronto, Canada. Electronic address: rob.hamilton@utoronto.ca.
² Department of Surgery (Urology), Princess Margaret Cancer Centre, University Health Network and The University of Toronto, Toronto, Canada.
³ Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
⁴ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

PMID: 31129064
DOI: 10.1016/j.euf.2019.05.003

Abstract

At Princess Margaret, we recommend active surveillance for all patients with clinical stage I nonseminomatous germ cell tumor. Here we refute common arguments against surveillance and urge clinicians to engage in a shared decision-making process that goes beyond merely citing relapse rates for the different options.

MeSH terms

Humans
Male
Neoplasm Staging
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / therapy*
Risk Assessment
Testicular Neoplasms / pathology
Testicular Neoplasms / therapy*
Watchful Waiting*

Supplementary concepts

Nonseminomatous germ cell tumor